Coenzyme Q10 Forte
Phase 3Small molecule
Coenzyme Q10 Forte is one of 60 small molecule programs targeting Outcome. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
54 competitors in Acute Coronary Syndrome
#DrugCompanyPhaseTrials
1Plavix
SanofiApproved
Brilinta
AstraZenecaApproved
Crestor
AstraZenecaApproved
Bayer Aspirin
BayerApproved
Colcrys
Jazz PharmaceuticalsApproved
Effient
CCosette Pharmaceuticals, Inc.
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Leqvio
NovartisApproved
Zyloprim
Jazz PharmaceuticalsApproved
Fragmin
PfizerApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Acute Coronary Syndrome1 trial
Coenzyme Q10 Role in Prevention of Contrast Induced Nephropathy in Acute Coronary Syndrome Patients.
Recruiting·—·Phase 4·NCT06429345·250 enrolled
Outcome1 trial
Effect of CoQ10 on the Outcome of MAFLD Patients
Recruiting·—·Phase 2·NCT05984745·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Coenzyme Q10 Forte. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAin Shams University